NCT05401019

Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD)

Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD): Randomized Controlled Trial

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Clinical Academic Center (2CA-Braga) · Academic / Other
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Not accepted

Summary

This is a phase 2, randomized, controlled clinical trial to study the efficacy of pramipexol or risperidone in the treatment of refractory ODC patients. This study is a two-parallel-group clinical trial with duration of 28 weeks (recruitment phase, 4 weeks + treatment phase, 16 weeks + follow-up phase, 8 weeks. The primary endpoint of this study is the score in the Y-BOCS scale measured between baseline and EOT ( at week 16).

Conditions

• Obsessive-Compulsive Disorder

Interventions

Type	Name	Description
DRUG	Pramipexole	Oral medication, once a day during 16 weeks
DRUG	Risperidone	Oral medication, once a day during 16 weeks

Timeline

• Start date: 2022-06-01
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2022-06-02
• Last updated: 2024-09-19